Differences in urinary proteins related to surgical margin status after radical prostatectomy

  • Authors:
    • Zbynek Heger
    • Petr Michalek
    • Roman Guran
    • Natalia Cernei
    • Katerina Duskova
    • Stepan Vesely
    • Jiri Anyz
    • Olga Stepankova
    • Ondrej Zitka
    • Vojtech Adam
    • Rene Kizek
  • View Affiliations

  • Published online on: October 2, 2015     https://doi.org/10.3892/or.2015.4322
  • Pages: 3247-3255
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Presented exploratory pilot study was aimed at evaluation of proteins present in urinary specimens collected from prostate cancer suffering subjects after radical prostatectomy, divided into two experimental cohorts: positive (n=15) and negative (n=15) surgical margins (PSM/NSM). The presence of PSM suggests inadequate cancer clearance and the possible need for additional treatment. Proper identification of these risk-patients is therefore of a paramount importance. Total protein profiles were firstly identified by using SDS-PAGE and compared by using partial least square discrimination analysis (PLS-DA), which revealed differences in molecular weights of 80-99 and 150-235 kDa between the experimental groups. For further identification of proteins, comparative proteomic technologies were employed. Two-dimensional gel electrophoresis with subsequent identification of protein spots by using MALDI-TOF mass fingerprinting revealed differential expression of proteins between NSM/PSM cohorts. Moreover, in PSM group, three uniquely identified proteins (cyclin-dependent kinase 6, galectin-3-binding protein and L-lactate dehydrogenase C chain) were found, which show tight connection with prostate cancer and presence of all of them was previously linked to certain aspects of prostate cancer. These proteins may be associated with the molecular mechanisms of prostate cancer development; hence, their identification may be helpful for the assessment of disease progression risk after radical prostatectomy, but also for possible early diagnosis.


Prostate cancer (PCa) is one of the most frequent malignant diseases of older men, whose incidence in Northern and Western Europe exceeds 200 new estimated cases/100,000 and is still growing, especially in the younger age group (35–64 years) (1). In European and North-American countries due to development of demography this disease becomes not only medical, but also an economical issue (2).

The cause of prostate cancer still remains unsolved and only few risk factors are known that affect development of malignant prostate disease. These include increasing age, the black race and hereditary factors (3,4). Not all forms of prostate cancer cause clinically significant disease. According to autopsy examinations 60–70% of older men die with prostate cancer, however only 3% of prostate cancer (5). Malignant disease is suspected on the basis of prostate-specific antigen (PSA) levels and palpation of the gland. Definitive diagnosis needs to be confirmed by transrectal needle biopsy.

Unfortunately, even with the sophisticated pre-operative staging techniques, an average of 28% of those undergoing radical prostatectomy are found to have positive surgical margins (6). A positive surgical margin (PSM) is defined as the presence of tumor at the inked surface of the resected specimen and as such implies incomplete excision of malignant tissue (7). These patients are at increased risk of biochemical relapse, 50–60% at 5 years, and subsequent clinical relapse, although by no means every patient will suffer eventual disease recurrence (8). Several explanations are given for why a PSM is not always associated with tumor recurrence. The surgery results in ischaemia and fibrosis, both of which may destroy small areas of residual carcinoma as the malignant tissue is unable to survive in its new environment. Alternatively, it may be a result of the desmoplastic response (6).

Evidence from randomized trials suggests that immediate secondary therapy is beneficial for patients with adverse pathology after surgery rather than watchful waiting (9). Since not all of the patients with PSM develop disease recurrence, physicians face the challenge of advising an individual on the necessity of secondary therapy. Potential non-invasive monitoring of presence of PSM can be helpful as an auxiliary tool in this decision making process. Recent advances in 'omics'-based technologies have greatly facilitated the possibilities to reliably study various types of molecules, linked to different pathological states (10). Among these, proteomics allows the comprehensive identification of broad spectrum of disease-specific proteins, which are important for detailed description of certain diseases, such as PCa (11). In particular, urinary proteins can serve as an informative tool, simply obtainable in sufficient amounts in non-invasive way.

Our current objective is therefore dual. First, we want to distinguish patients with confirmed PSM or NSM after radical prostatectomy by using sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and its subsequent statistical processing by partial least squares discriminant analysis (PLS-DA). Secondly, we want to identify the major protein differences between the groups by using 2-D PAGE and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF) a powerful tool for proteomics application. Overall, the disparities in expression of urinary proteins in PSM and NSM groups are highlighted.

Materials and methods

Chemical compounds

All reagents employed for study, as standards, and others were purchased from Sigma-Aldrich (St. Louis, MO, USA) in ACS purity, unless noted otherwise.

Clinical urinary samples

For purpose of this study, urine samples from patients suffering from prostate cancer (n=30), obtained from University Hospital in Motol, Department of urology, Prague, Czech Republic, were studied (Table I). All the samples were obtained 3 months after radical prostatectomy. Tested patients were divided into two experimental groups. The first one consisted of patients with negative surgical margins (NSM) (n=15). The second group consisted of patients with PSM (n=15). Enlistment of patients into realized clinical study was approved by the Ethics committee (reference EK-377/13).

Table I

Stratification of the patients from whom urinary samples were collected.

Table I

Stratification of the patients from whom urinary samples were collected.

PatientTNM stageSurgical margin statusGleason scorePSA (ng/ml) in 3rd month after the surgery

[i] 1–15 indicate the patients belonging to NSM group; 16–30 indicate the patients from PSM, both after radical prostatectomy.

Tumors were staged according to the 2002 TNM staging system. Extraprostatic extension (pT3a, pT3b) was defined as the extension of the tumor beyond the confines of the gland into the periprostatic soft tissue. A PSM was defined as the presence of tumor at the inked surface of the resected specimen. Histological Gleason grading was performed by a dedicated genitourinary pathologist. Level of serum PSA was measured 3 months after the surgery and this test was performed in a single hospital laboratory under standardized settings.

Determination of total protein in urinary samples

Total protein was quantified using the Skalab 600 M kit (Skalab, Svitavy, Czech Republic), according to the manufacturer's instructions. Measurements were carried out on automated spectrophotometer BS-400 (Mindray, Shenzhen, China).

Acetone precipitation of urinary proteins

Urinary samples (50 µl) were added to 200 µl of acetone. The mixtures were stored for 3 h at −20°C and further were centrifuged using Microcentrifuge 5417R (Eppendorf AG, Hamburg, Germany) under 10,000 g at 4°C for 15 min. The pellets were washed with diethylether and ethanol mixture (6:1) and centrifuged (10,000 g at 4°C, 5 min), then solvent was removed and the pellet was dried on air.

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)

Pellets were diluted in 5 µl of ACS water, mixed with protein loading buffer (PLB) in a ratio of 1:1 and incubated at 95°C for 5 min in Thermomixer® R (Eppendorf AG). Further, samples were removed into the wells in the 12.5% polyacrylamide gel. Electrophoresis was performed in 1X Tris-glycine-SDS running buffer for 60 min in the electrophoretic bath (Bio-Rad, Berkeley, CA, USA) at 110 v. Gels were visualized following protocol of staining with Coomassie brilliant blue staining (12).

Data collection

The decision was made to describe each individual by series of values as curves extracted from electr phoreograms. This approach was chosen among other alternatives namely description of individuals by pairs of band positions and intensities due to its advantages in application of machine learning algorithms. A set of curves can be easily transformed into data matrix in comparison with other descriptions of individuals. The extraction of curves and estimation of molecular weight was made according to ref. 13. The data collection was facilitated by the MATLAB programming language.

Exploratory analysis

Exploratory analysis was performed by examining tables and plots of the observed data. The transformation was identified to evaluate the raw data on the basis of plots and knowledge of the expected scale of measured variables. Exploratory analysis was used to: i) identify missing and outlying values, ii), verify the quality of the data and find appropriate corrections, and iii) to determine the intervals of spectra used in the projection to latent structure discriminant analysis model relating outputs of experiments to predictors according to the experimental settings.

Statistical modeling

The standard projection to latent structure discriminant analysis models (PLS-DA) were used to find parts of curves differing in examined groups according to experimental settings. The standard PLS 1 algorithm was used to construct latent variables and ordinary least squares were used to determine the coefficients of classification model relating the latent variables to output of the experiment. The leave-one-out validation was used to assess the quality of different models and to choose the correct number of latent variables with respect to the performance of model on the validation data set. The fraction of explained variation R2 was also computed to provide more detailed evaluation of trained models. The interpretation of PLS-DA models was performed by the examination of loading plots and S plots. The interesting parts of curves in relation to the response were pointed out by introducing limits to denominated values in S plots.

2-D PAGE analysis

Pellets, collected after acetone precipitation were diluted in 125 µl of rehydration buffer (2 M urea, 7 M thiourea, 4% 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate hydrate, 100 mM dithiothreitol, 0.2% ampholyte with pH 3.0–10.0, 0.001% bromophenol blue), and the solution was sonicated (8×2 sec). The resulting solution was employed for 12-h rehydration on 7-cm IPG strips (Bio-Rad). The IPG strips, after rehydration, were focused on Protean® IEF cell (Bio-Rad) at 20°C in 3 steps. In the first step, electric voltage was increased linearly over 20 min from 0 to 250 V. Second step comprised the voltage increase to 4,000 V (maintained for 2 h). In the third step the electrical parameters were set so that the total value reached 10 kvh. The electric current was limited to the value of 50 mA/strip. After isoelectric focusing, strips were incubated for 10 min at 25°C on a shaker with the First equilibration buffer [6 M urea, 20% v/v glycerol, 2% w/v SDS, 0.375 M Tris-HCL (ph 8.8), 2% w/v dithiothreitol]. Thereafter, the solution was replaced and the strips were incubated with the second equilibration buffer [6 M urea, 20% v/v glycerol, 2% w/v SDS, 0.375 M Tris-HCL (pH 8.8), 2.5% w/v iodacetamide, 0.001% bromophenol blue] for 10 min. Strips, prepared in this manner were washed in Tris glycine-SDS running buffer. The strips were then placed on the back of the flatbed electrophoretic glass plate. Subsequently, the agarose was poured between the plates, where the strip was inserted. After solidification of agarose, the plates were inserted in the electrophoretic bath with Tris-glycine-SDS running buffer. Electrophoresis was set to 75 min at a voltage of 180 V. Gels were stained using coomassie brilliant blue and silver (12).

In-gel tryptic digestion

For excision of the spots from 2D gels of urinary samples EXQuest™SpotCutter (Bio-Rad) was utilized. The in-gel digestion with trypsin was performed according to a protocol of Shevchenko et al (14). The digests of proteins were further employed for peptide mass fingerprinting (PMF).

Matrix-assisted laser Desorption/Ionization time-of-flight (MALDI-TOF)

The mass spectrometry experiments were performed on a MALDI-TOF mass spectrometer Bruker ultrafleXtreme (Bruker Daltonik Gmbh, Bremen, Germany), using 2,5-dihydroxybenzoic acid as matrix. The saturated matrix solution was prepared in 30% acetonitrile and 0.1% trifluoroacetic acid. Mixture was thoroughly vortexed and ultrasonicated using Bandelin 152 Sonorex Digital 10P ultrasonic bath (Bandelin Electronic, Berlin, Germany) for 2 min at 50% of intensity at room temperature. For sample preparation the dried-droplet method was utilized, where solutions of digested proteins were mixed with matrix solution in volume ratio of 1:1. After obtaining a homogeneous solution, 2 µl was applied on the MTP 384 polished steel target plate (Bruker Daltonik Gmbh) and dried under atmospheric pressure at 25°C. All measurements were performed in the reflector positive mode in the m/z range 400–6,000 Da. The MS spectra were typically acquired by averaging 500 sub spectra from a total of 500 shots of the laser with laser power set 5% above the threshold.

Peptide mass fingerprinting

Peptide mass fingerprinting (PMF) was done using MASCOT server (Matrix Science, Boston, MA, USA) for comparing mass spectra with UniProt database. For database search the following parameters were used: trypsin was used as the enzyme, zero or one missed cleavage was allowed, taxonomy was set to Homo sapiens, oxidation of methionine or/and N-term acetylation was added as variable modification, peptide tolerance was set to ±0.5 Da, mass values were set as Mh+ and were obtained from monoisotopic peaks.

Results and Discussion

Urine is a specific filtrate of blood; the protein components of urine are qualitatively similar to those of blood but much more diluted (15). An advantage for urine over blood is that urinary proteins are stable and do not undergo significant proteolysis within several hours of collection. Hence, urinary proteomics presents an attractive approach to cancer biomarker discovery, not only for urological malignancies (16), but for other systemic malignancies and evaluation of current health status (17). Many advantages favor the use of urine over blood and tissues samples, including the fact that urine-based tests are non-invasive, and urine is non-infectious for HIV and less infectious for many other pathogens (18).

Evaluation of total protein profiling by SDS-PAGE and its statistical processing

The migration of the molecular weight marker and urinary proteins of NSM, PSM patients on SDS-PAGE is presented in Fig. 1A. SDS-PAGE is a rapid and simple technique for protein pattern elucidation, quantification and determination of groups of proteins with similar molecular weight (Mr) (19). The visualization of NSM/PSM groups revealed proteins with relatively wide range of Mr that, according to previously published results, correspond to commonly present albumin (Mr 60–70 kDa); 80–110 kDa range belongs to transferrin and uromodulin (formerly Tamm-Horsfall protein), together with albumin polymeric complexes can be determined, in 160–200 kDa range the major band is commonly dedicated to IgG, IgA monomers and C3. Less distinct bands at Mr 31 kDa were previously linked with carbonic anhydrase (2022). For confirmation, total proteins in urinary specimens were quantified spectrophotometrically (Fig. 1B). Higher protein levels were determined in PSM cohort (85.3±55.9 mg/l) when compared to NSM one (mean 64.1±36.2 mg/l).

Since our first aim was the determination of NSM/PSM SDS-PAGE protein patterns we employed partial least square discriminant analysis (PLS-DA) model, which utilized curves (band intensities) extracted from SDS-PAGE gels. To facilitate the comparability of curves the linear interpolation of all curves was carried out to identical values of molecular weight. Carrying out the linear interpolation a pair of limits was introduced to exclude marginal parts of curves and the linearization of molecular weight was performed. The leave-one-out validation was carried out to assess the prediction quality of the model and to choose the number of latent variables according to the prediction accuracy criterion. The results of leave-one-out validation of PLS DA model are presented in Table II.

Table II

The evaluation of partial least square discriminant analysis (PLS-DA) model.

Table II

The evaluation of partial least square discriminant analysis (PLS-DA) model.

ModelPerformance on the validation setFraction of explained variationEstimated no. of latent variables

As seen in Fig. 2A, in our NSM/PSM model the proteins in mass ranges of 80–99 and 150–235 kDa were evaluated as the most significant in discrimination between examined groups. The quadrant expression based on comparison of the curves projection shows separate distribution of both NSM and PSM groups (Fig. 2B).

Obtained results revealed interesting disparities in protein patterns; however co-migration of proteins with similar mass decreased the separation yields and thus better separation method was required for further analyses of proteins of interest.

2-D electrophoresis and PMF

Because two-dimensional gel electrophoresis employs both isoelectric focusing of target molecule, its Mr and it is unlikely that two molecules will be similar in two distinct properties, higher separation resolution is provided (23). We analyzed urinary protein profiles of patients with NSM (n=15) and PSM (n=15) by using acetone precipitation for proteins isolation with subsequent 2-D electrophoresis and MALDI-TOF identification.

Following 2D-PAGE and staining, the most prominent spots were picked up for the MS analysis. Their positions in the 2-D map of representative subject belonging to PSM group are shown in Fig. 3A. Some proteins were presented as a horizontal row of multiple spots (with small changes in pI and molecular weight), likely caused by variable posttranslational modifications (24). The identified proteins and their characteristics are shown in Table III. It was revealed that majority of proteins (19 overlaping proteins) can be identified in both groups. In both, PSM and NSM groups, unique proteins were found (n=1 in NSM; n=3 in PSM) as depicted in Fig. 3B.

Table III

Expression of basic characteristics and abundance of proteins (%), identified in both groups (NSM, n=15, PSM, n=15) after in-gel tryptic digestion and MALDI-TOF identification.

Table III

Expression of basic characteristics and abundance of proteins (%), identified in both groups (NSM, n=15, PSM, n=15) after in-gel tryptic digestion and MALDI-TOF identification.

No.ProteinUniProt accession entryPredicted mass (Mr)pIApprox. MASCOT scoreNSM (%)PSM (%)
2AT-rich interactive domain-containing protein 1AARI1A_HUMAN242.06.083676727
3Cyclin-dependent kinase 6CDK6_HUMAN36.96.0235840
6Fatty acid-binding protein, intestinalFABPI_HUMAN15.25.302582740
7Galectin-3-binding proteinLG3BP_HUMAN65.34.9055953
8Keratin, type I cytoskeletal 10K1C10_HUMAN58.85.103986787
9Keratin, type I cytoskeletal 9K1C9_HUMAN62.04.901579453
10Keratin, type II cytoskeletal 1K2C1_HUMAN66.08.103047367
11L-lactate dehydrogenase C chainLDHC_HUMAN36.27.0845627
13Protein disulfide-isomerase A4PDIA4_HUMAN72.95.162646073
14Retinol-binding protein 1RET4_HUMAN20.55.764417367
16Serum albuminALBU_HUMAN69.34.70360100100
17Testis-expressed sequence 33 proteinTEX33_HUMAN30.75.6525627
19Acid phosphatase, prostatePPAP_HUMAN44.55.892563773
20Guanine nucleotide binding proteinGBLP_HUMAN40.45.694015367
21Serine proteinase inhibitor, clade A A0A024R6N9_HUMAN46.65.423013453
22CD59 glycoproteinCD59_HUMAN14.26.022995387
23 Lithostathine-1-αREG1A_HUMAN18.75.001788773

[i] The identified proteins including the UniProt identification number, predicted pI and the molecular weight (kDa) are summarized. All of the proteins showed on Fig. 3 are in the expected range of pI and molecular weight.

The identified proteins were further classified using the data from the UniProt knowledgebase. As shown in Fig. 4A, belonging to PSM group, regarding to molecular functions, most of identified proteins (46%) have binding function, which was followed by catalytic activity, transport and organization of cellular components. Proteins (21%) were involved in response to stimuli, followed by cellular and metabolical processes (18%). One third of identified proteins are enzymes (35%) and most of proteins had extracellular region location (41%). The majority of extracellular proteins is related to close contact of urine with glands in the male urinary tract and fact that significant fraction of urinary proteins is derived from plasma (25). In NSM group (Fig. 4B), lower portion of binding proteins (37%) was observed with increase of transport proteins (21%) and proteins responsible for organi-zation of cellular components (24%). Further, in NSM group, decreased number of enzymes was identified and in four subjects, elevated expression of testis-expressed sequence 33 protein (TEX33_HUMAN), protein with unknown function and biological role, was determined. In NSM cohort, higher abundance of E-cadherin, calcium 2+-dependent cell-adhesion protein, maintaining homeostasis (26), was determined. Several reports show that E-cadherin is tumor-invasive suppressor and decreased cadherin expression has been associated with more advanced tumor stage, grade and poor prognosis in PCa (2729). Shimamura and coworkers demonstrated that patients suffering from pancreatic adenocarcinoma with downregulated E-cadherin had a tendency to have PSM (30). α fetoprotein, potential tumor biomarker (31), was identified (27%), in lower abundance in NSM group, which points at possible higher relapse potential of PSM subjects. Another interesting finding was the disparity in urinary prostatic acid phosphatase (Table III). In 1936 Gutman and coworkers observed that serum activity of this enzyme is significantly higher in PCa patients, especially suffering from osteoplastic metastases (32), and it was extensively used for PCa diagnosis prior to introduction of PSA (33). Our results demonstrate that PSM cohort comprises more subjects, whose urinary specimens contain detectable levels (73%) of prostatic acid phosphatase when compared to NSM group (37%). In NSM cohort, also higher abundance of plasminogen (angiostatin), potent inhibitor of angiogenesis (34), was determined.

From all identified proteins, 3 unique proteins have been determined in PSM group, whose expression in NSM group is downregulated to undetectable levels. All of them (cyclin-dependent kinase 6, L-lactate dehydrogenase C chain and retinol-binding protein) were determined in more than one case (27–67% abundance), which points to their possible connection with presence of residual tumor tissue. The list of these proteins with a description of their biological role is shown in Table IV.

Table IV

Characterization of functions of the 3 unique proteins found only in the PSM group.

Table IV

Characterization of functions of the 3 unique proteins found only in the PSM group.

ProteinGeneSubcellular locationBiological functionDescribed linkage to PCa(Ref.)
Cyclin-dependent kinase 6CDK6Nucleus, cytoplasmControl of cell cycle and differentiation, promotes G1/S transitionYes(36)
Galectin-3-binding protein LGALS3BPExtracellular regionPromotes integrin-mediated cell adhesion, stimulate host defense against tumor cellsYes(37)
L-lactate dehydrogenase C chainLDHCCytoplasmPossible role in sperm motility, conversion of L-lactate and NAD to pyruvate and NADH in anaerobic glycolysisYes(38)

The identified proteins, unique for PSM cohort were previously described in certain aspects of prostate cancer development. Cyclin-dependent kinase 6 (CDK6) binds to and is activated by cyclin D1 and thereby enhances the transition of cells through the G1 phase (35). The regulation is performed through regulation of the phosphorylation state of retinoblastoma protein (pRb). When hyperphosphorylation of pRb occurs, it leads to release of transcription factors, which enhance progression of the cell cycle (36). Since the dysregulation of the cell cycle is one of the defined hallmarks of cancer (37), Palbociclib, oral inhibitor of CDK4/6, was developed to manage ER+ and HER2 amplified breast tumors (38). In prostate cancer only slight evidence exists pointing to a role of CDK6. Lim et al (35) demonstrated that CDK6 can easily bind to the androgen receptors (AR), which play a pivotal role in prostate cancer (39), and it was revealed that CDK6/AR binding stimulates transcriptional activity in presence of dihydrotestosterone (35). Moreover, they have shown that androgen-sensitive LNCaP PCa cells, engineered to stably overexpress CDK6 display increased elevated PSA expression and enhanced growth attributes. The same group indicates that CDK6 is overexpressed in 44% of PCa; hence presence of this protein in urine could be clinically interesting for evaluation of post-prostatectomy status.

Another uniquely identified protein, connected with PSM status was galectin-3-binding protein (also named Mac-2BP or tumor-associated antigen 90K) that is a highly glycosylated secreted protein, capable of inducing the expression of number of cytokines (IL-1, IF-2 and IL-6) (40). Previous studies have indicated that galectin-3-binding protein promotes tumor metastasis and that the tumor promotion mechanism in metastasis is associated with galectins (41). Furthermore, it was revealed that galectin-3-binding proteins enhance tumor cell adhesion, which may aid tumor cells to avoid apoptosis and is thus highly expressed in PCa samples (42). Although the potential of serum galectin-3-binding protein was discussed in several reports (40,42,43), to our knowledge, this is the first report, showing its possible diagnostic utilization in analysis of urinary specimens.

L-lactate dehydrogenase C chain or the cancer/testis antigen 32 is typically expressed in normal male germ cells but are silent in normal somatic cells. Nevertheless, they are aberrantly expressed in several types of cancer, including PCa (44). Several studies shown that the expression of L-lactate dehydrogenase C chain is frequently associated with higher grade lesions and advanced disease with a poorer outcome (45,46), which is consistent with the general fact that PSM is more often linked with higher Gleason score and higher pathologic stage (47) (higher TNM and GS of PSM subjects are shown in Table I).

In conclusion, our examination of urinary proteomes of human Pca specimens identified differences between groups of patients with positive and negative surgical margins after radical prostatectomy. The significance of these findings in the context of presence of PSM is represented by molecular changes leading to alterations in biochemical pathways, hopefully related to the presence of residual tumor after surgical treatment failure. Further evaluation of proteomes of PSM/NSM patients and observation of their biochemical and clinical recurrence will be needed to address a potential significance of urinary proteins in this phenomenon. Ultimately, development of combination of genomic-proteomic approaches for monitoring of biological processes will be fundamental in further endeavors to understand the PCa and PCa-related statuses in detail.


The authors are grateful to CEITEC CZ.1.05/1.1.00/02.0068 and research grant IGA MZ CR NT13472-4 for financial support.



Arnold M, Karim-Kos HE, Coebergh JW, Byrnes G, Antilla A, Ferlay J, Renehan AG, Forman D and Soerjomataram I: recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. Eur J Cancer. 51:1164–1187. 2015. View Article : Google Scholar


Luengo-Fernandez R, Leal J, Gray A and Sullivan R: Economic burden of cancer across the European Union: A population-based cost analysis. Lancet Oncol. 14:1165–1174. 2013. View Article : Google Scholar : PubMed/NCBI


Sakr WA, Haas GP, Cassin BF, Pontes JE and Crissman JD: The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. J Urol. 150:379–385. 1993.PubMed/NCBI


Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI


Haas GP, Delongchamps N, Brawley OW, Wang CY and de la Roza G: The worldwide epidemiology of prostate cancer: Perspectives from autopsy studies. Can J Urol. 15:3866–3871. 2008.PubMed/NCBI


Walsh PC, Partin AW and Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy: Results at 10 years. J Urol. 152:1831–1836. 1994.PubMed/NCBI


Watson RB, Civantos F and Soloway MS: Positive surgical margins with radical prostatectomy: Detailed pathological analysis and prognosis. Urology. 48:80–90. 1996. View Article : Google Scholar : PubMed/NCBI


Cheng L, Darson MF, Bergstralh EJ, Slezak J, Myers RP and Bostwick DG: Correlation of margin status and extraprostatic extension with progression of prostate carcinoma. Cancer. 86:1775–1782. 1999. View Article : Google Scholar : PubMed/NCBI


Vesely S, Jarolim L, Duskova K, Schmidt M, Dusek P and Babjuk M: The use of early postoperative prostate-specific antigen to stratify risk in patients with positive surgical margins after radical prostatectomy. BMC Urol. 14:792014. View Article : Google Scholar : PubMed/NCBI


Aebersold R, Anderson L, Caprioli R, Druker B, Hartwell L and Smith R: Perspective: A program to improve protein biomarker discovery for cancer. J Proteome Res. 4:1104–1109. 2005. View Article : Google Scholar : PubMed/NCBI


Bergman N and Bergquist J: Recent developments in proteomic methods and disease biomarkers. Analyst (Lond). 139:3836–3851. 2014. View Article : Google Scholar


Heger Z, Kominkova M, Cernei N, Krejcova L, Kopel P, Zitka O, Adam V and Kizek R: Fluorescence resonance energy transfer between green fluorescent protein and doxorubicin enabled by DNA nanotechnology. Electrophoresis. 35:3290–3301. 2014. View Article : Google Scholar : PubMed/NCBI


Vyslouzilova L, Krizkova S, Anyz J, Hynek D, Hrabeta J, Kruseova J, Eckschlager T, Adam V, Stepankova O and Kizek R: Use of brightness wavelet transformation for automated analysis of serum metallothioneins- and zinc-containing proteins by western blots to subclassify childhood solid tumours. Electrophoresis. 34:1637–1648. 2013. View Article : Google Scholar : PubMed/NCBI


Shevchenko A, Tomas H, Havlis J, Olsen JV and Mann M: In-gel digestion for mass spectrometric characterization of proteins and proteomes. Nat Protoc. 1:2856–2860. 2006. View Article : Google Scholar


Oh J, Pyo JH, Jo EH, Hwang SI, Kang SC, Jung JH, Park EK, Kim SY, Choi JY and Lim J: Establishment of a near-standard two-dimensional human urine proteomic map. Proteomics. 4:3485–3497. 2004. View Article : Google Scholar : PubMed/NCBI


Rehman I, Azzouzi AR, Catto JWF, Allen S, Cross SS, Feeley K, Meuth M and Hamdy FC: Proteomic analysis of voided urine after prostatic massage from patients with prostate cancer: A pilot study. Urology. 64:1238–1243. 2004. View Article : Google Scholar : PubMed/NCBI


Ye B, Skates S, Mok SC, Horick NK, Rosenberg HF, Vitonis A, Edwards D, Sluss P, Han WK, Berkowitz RS, et al: Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res. 12:432–441. 2006. View Article : Google Scholar : PubMed/NCBI


Botezatu I, Serdyuk O, Potapova G, Shelepov V, Alechina R, Molyaka Y, Ananév V, Bazin I, Garin A, Narimanov M, et al: Genetic analysis of DNA excreted in urine: A new approach for detecting specific genomic DNA sequences from cells dying in an organism. Clin Chem. 46:1078–1084. 2000.PubMed/NCBI


Oh J, Wilson L, Kirk M, Deshane J and Kim H: Proteomics of normal human and prostate cancer urines. FASEB J. 17:759.7572003.


Kshirsagar B and Wiggins RC: A map of urine proteins based on one-dimensional SDS-polyacrylamide gel electrophoresis and western blotting using one microliter of unconcentrated urine. Clin Chim Acta. 158:13–22. 1986. View Article : Google Scholar : PubMed/NCBI


Zaragoza C, Barrera R, Centeno F, Tapia JA and Mañe MC: Canine pyometra: A study of the urinary proteins by SDS-PAGE and western blot. Theriogenology. 61:1259–1272. 2004. View Article : Google Scholar : PubMed/NCBI


Le Bricon T, Erlich D, Bengoufa D, Dussaucy M, Garnier JP and Bousquet B: Sodium dodecyl sulfate-agarose gel electrophoresis of urinary proteins: Application to multiple myeloma. Clin Chem. 44:1191–1197. 1998.PubMed/NCBI


Marshall T and Williams KM: High resolution two-dimensional electrophoresis of human urinary proteins. Anal Chim Acta. 372:147–160. 1998. View Article : Google Scholar


Thongboonkerd V, McLeish KR, Arthur JM and Klein JB: Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int. 62:1461–1469. 2002. View Article : Google Scholar : PubMed/NCBI


Adachi J, Kumar C, Zhang Y, Olsen JV and Mann M: The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol. 7:R802006. View Article : Google Scholar : PubMed/NCBI


Day ML, Zhao X, Vallorosi CJ, Putzi M, Powell CT, Lin C and Day KC: E-cadherin mediates aggregation-dependent survival of prostate and mammary epithelial cells through the retinoblastoma cell cycle control pathway. J Biol Chem. 274:9656–9664. 1999. View Article : Google Scholar : PubMed/NCBI


Cheng L, Nagabhushan M, Pretlow TP, Amini SB and Pretlow TG: Expression of E-cadherin in primary and metastatic prostate cancer. Am J Pathol. 148:1375–1380. 1996.PubMed/NCBI


Umbas R, Isaacs WB, Bringuier PP, Schaafsma HE, Karthaus HF, Oosterhof GO, Debruyne FM and Schalken JA: Decreased E-cadherin expression is associated with poor prognosis in patients with prostate cancer. Cancer Res. 54:3929–3933. 1994.PubMed/NCBI


Giroldi LA and Schalken JA: Decreased expression of the intercellular adhesion molecule E-cadherin in prostate cancer: Biological significance and clinical implications. Cancer Metastasis Rev. 12:29–37. 1993. View Article : Google Scholar : PubMed/NCBI


Shimamura T, Sakamoto M, Ino Y, Sato Y, Shimada K, Kosuge T, Sekihara H and Hirohashi S: Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: Relationship to e-cadherin expression. J Clin Oncol. 21:659–667. 2003. View Article : Google Scholar : PubMed/NCBI


Duffy MJ: Tumor markers in clinical practice: A review focusing on common solid cancers. Med Princ Pract. 22:4–11. 2013. View Article : Google Scholar


Gutman EB, Sproul EE and Gutman AB: Significance of increased phosphatase activity of bone at the site of osteoplastic metastases secondary to carcinoma of the prostate gland. Am J Cancer. 28:485–495. 1936. View Article : Google Scholar


Wang MC, Papsidero LD, Kuriyama M, Valenzuela LA, Murphy GP and Chu TM: Prostate antigen: A new potential marker for prostatic cancer. Prostate. 2:89–96. 1981. View Article : Google Scholar : PubMed/NCBI


Morikawa W, Yamamoto K, Ishikawa S, Takemoto S, Ono M, Fukushi J, Naito S, Nozaki C, Iwanaga S and Kuwano M: Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. J Biol Chem. 275:38912–38920. 2000. View Article : Google Scholar : PubMed/NCBI


Lim JTE, Mansukhani M and Weinstein IB: Cyclin-dependent kinase 6 associates with the androgen receptor and enhances its transcriptional activity in prostate cancer cells. Proc Natl Acad Sci USA. 102:5156–5161. 2005. View Article : Google Scholar : PubMed/NCBI


Choi YJ and Anders L: Signaling through cyclin D-dependent kinases. Oncogene. 33:1890–1903. 2014. View Article : Google Scholar


Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI


Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al: PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009. View Article : Google Scholar : PubMed/NCBI


Tan MHE, Li J, Xu HE, Melcher K and Yong EL: Androgen receptor: Structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin. 36:3–23. 2015. View Article : Google Scholar :


Sardana G, Marshall J and Diamandis EP: Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. Clin Chem. 53:429–437. 2007. View Article : Google Scholar : PubMed/NCBI


Inohara H, Akahani S, Koths K and Raz A: Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res. 56:4530–4534. 1996.PubMed/NCBI


Hu J, He J, Kuang Y, Wang Z, Sun Z, Zhu H and Liu X: Expression and significance of 90k/Mac-2BP in prostate cancer. Exp Ther Med. 5:181–184. 2013.


Srirajaskanthan R, Caplin ME, Waugh MG, Watkins J, Meyer T, Hsuan JJ and Beaumont NJ: Identification of Mac-2-binding protein as a putative marker of neuroendocrine tumors from the analysis of cell line secretomes. Mol Cell Proteomics. 9:656–666. 2010. View Article : Google Scholar :


Scanlan MJ, Simpson AJG and Old LJ: The cancer/testis genes: Review, standardization, and commentary. Cancer Immun. 4:1–15. 2004.PubMed/NCBI


Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, Ritter G, Simpson AJ, Chen YT, Old LJ, et al: Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 11:8055–8062. 2005. View Article : Google Scholar : PubMed/NCBI


Andrade VCC, Vettore AL, Almeida MSS, et al: Prognostic impact of cancer testis antigens expression in advanced stage multiple myeloma patients. Blood. 110:257B. 2007.


Marcovich R, Wojno KJ, Wei JT, Rubin MA, Montie JE and Sanda MG: Bladder neck-sparing modification of radical prostatectomy adversely affects surgical margins in pathologic T3a prostate cancer. Urology. 55:904–908. 2000. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

Volume 34 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
Spandidos Publications style
Heger Z, Michalek P, Guran R, Cernei N, Duskova K, Vesely S, Anyz J, Stepankova O, Zitka O, Adam V, Adam V, et al: Differences in urinary proteins related to surgical margin status after radical prostatectomy. Oncol Rep 34: 3247-3255, 2015
Heger, Z., Michalek, P., Guran, R., Cernei, N., Duskova, K., Vesely, S. ... Kizek, R. (2015). Differences in urinary proteins related to surgical margin status after radical prostatectomy. Oncology Reports, 34, 3247-3255. https://doi.org/10.3892/or.2015.4322
Heger, Z., Michalek, P., Guran, R., Cernei, N., Duskova, K., Vesely, S., Anyz, J., Stepankova, O., Zitka, O., Adam, V., Kizek, R."Differences in urinary proteins related to surgical margin status after radical prostatectomy". Oncology Reports 34.6 (2015): 3247-3255.
Heger, Z., Michalek, P., Guran, R., Cernei, N., Duskova, K., Vesely, S., Anyz, J., Stepankova, O., Zitka, O., Adam, V., Kizek, R."Differences in urinary proteins related to surgical margin status after radical prostatectomy". Oncology Reports 34, no. 6 (2015): 3247-3255. https://doi.org/10.3892/or.2015.4322